-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s PR-001
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's PR-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketamine Hydrochloride PR in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketamine Hydrochloride PR in Treatment Resistant Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ketamine Hydrochloride PR in Treatment Resistant Depression Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PR-15 in Acute Coronary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PR-15 in Acute Coronary Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PR-15 in Acute Coronary Syndrome Drug Details: PR-15 (revacept, GPVI-Fc) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PR-15 in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PR-15 in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PR-15 in Peripheral Arterial Disease (PAD)/...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s PRS-060
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's PRS-060 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Prometheus Biosciences Inc’s PR-200
Empower your strategies with our Net Present Value Model: Prometheus Biosciences Inc's PR-200 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s PR-006
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's PR-006 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Buprenorphine PR in Chronic Low Back Pain (CLBP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Buprenorphine PR in Chronic Low Back Pain (CLBP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Buprenorphine PR in Chronic Low Back Pain (CLBP)...
-
Company Insights
Innovation and Patenting activity of PR TIMES, Inc. Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PR TIMES, Inc. Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval Analysis for Hormone Sensitive Breast Cancer
Overview How likely is it that the drugs in Hormone Sensitive Breast Cancer will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hormone Sensitive Breast Cancer Overview Estrogen and progesterone promote the...